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Abstract 
Owing to its rarity, large-scale retrospective
studies in male breast cancer have suffered from
the small numbers of cases available for study
from any one center. Here we describe our expe-
rience in establishing a large collection of male
breast cancers in tissue micro  array format suit-
able  for  biomarker  analysis  by  immunohisto-
chemistry.
Male breast tissue lies posterior to the nipple
on the chest wall. It is generally considered non-
functional; while lactation is physiologically pos-
sible it is very rare, requiring specific hormonal
cues.
1 Although not exposed to the same cyclical
hormones as the pre-meno  pausal female breast,
male breast epithelium is not immune to DNA
damage, and with the acquisition of both onco-
genic activation and compromised DNA repair
mechanisms,  carcinoma  formation  can  occur.
Breast cancer in men is rare however, account-
ing for about 1% of all breast cancers. Current
estimates put this at around 300 cases in the
U.K.
2 and 1900 in the U.S.
3 annually. The most
common type of breast cancer in men is ductal
carcinoma of no specific type (NST) followed by
papillary carcinoma, the latter being an uncom-
mon female breast cancer subtype.
4 Lobular car-
cinoma is uncommon, an observation originally
thought to be a consequence of the scarcity/lack
of lobules in most male breasts; however, given
modern understanding of the genesis of the lob-
ular carcinoma morphology through inactivation
of  E-cadherin,
5 the  explanation  is  likely  to  be
more subtle. Retrospective studies of male breast
cancer, in particular those defining prognosis,
have suffered from the small numbers of cases
available  from  any  one  center.  Our  research
institute in the U.K. is affiliated to the Leeds
Teaching  Hospital  NHS  Trust,  currently  the
largest teaching hospital in Europe, yet we gen-
erally see no more than five cases of male breast
cancer annually. Thus a significant problem in
studying male breast cancer is accruing suffi-
ciently large numbers to allow robust biological
studies. Although reasonably large numbers of
male breast cancer cases have been identified
from tumor registries; for example, 241 in the
Veterans Administration tumor registry
6 and 111
from the archives of the Mayo Clinic,
7only 65 and
72 patients, respectively, had complete follow-up
data and pathology blocks available for immuno-
histochemistry. The largest male breast cancer
series evaluated 778 cases collected over 40 years
from  the  U.S.  Armed  Forces  Institute  of
Pathology.
4 This  descriptive  study  investigated
frequencies and distribution of histopathological
subtypes  compared  to  female  breast  cancer.
Large collections like this would be a very valu-
able resource to study male breast cancer but
contact with the corresponding author revealed
that the group has since dispersed and the blocks
were not available (personal communication). To
tackle this problem, we adopted a co-ordinated
multi-center  approach.  Following  ethical
approval from the Leeds (West) Research Ethics
Committee,  Leeds,  U.K.  (06/Q1205/156),  we
identified 129 cases from our local archive. In
addition to these cases, we approached patho  -
logists within the U.K. and overseas and named
this the Male Breast Cancer Study Consortium.
We have experienced a tremendous amount of
goodwill toward accruing this collection with all
of  the  groups  we  contacted  willing  to  provide
cases. Throughout this process a key element
has been direct engagement with histopatholo-
gists. On receipt in our laboratory, cases were
anonymized and hematoxylin-eosin sections pre-
pared. Following inspection of these sections, 0.6
mm cores were removed from the most represen-
tative  tumor  area  and  assimilated  into  tissue
microarrays (TMAs). This provided a means of
preserving the longevity of the resource, thus
maximizing the amount of information that can
be obtained. Donor blocks were returned prompt-
ly to the original centers. To date we have collect-
ed a total of 386 cases from six different coun-
tries. In addition we have collected comprehen-
sive clinical details from as many cases as possi-
ble, including: date of diagnosis and surgical pro-
cedure, age, tumor size, grade, type, TNM stage,
type  of  treatment  (chemo/endocrine  therapy,
adjuvant/neoadjuvant), nodal status, recurrence,
family history, and survival. We have used our
TMAs to analyze over 25 biomarkers including
those associated with hormone receptors, prolif-
eration, angiogenesis, apoptosis, tumor taxono-
my, and therapeutic markers. Publications are in
the  pipeline.  A  collection  of  this  nature  has
allowed a much-needed, large-scale study of male
breast cancer. As male breast cancer is rising,
8
our collection represents an important resource
for future testing of new biomarkers that may
have  prognostic  or  predictive  significance,  as
well  as  for  comparative  studies  with  matched
female  breast  cancer,  something  that  has  not
been possible with smaller collections owing to
the well-recognized heterogeneity of breast can-
cer. Finally, it has been reported recently that the
Breast International Group and North American
Breast Cancer Group have joined forces to devel-
op an International Male Breast Cancer Program
to pool specimens, and clinical and epidemiolog-
ical data, with the long-term goal of facilitating
clinical trials for male breast cancer.
9We applaud
this initiative. With male breast cancer prognosis
and treatment derived exclusively from female
breast cancer studies, together these collections
should increase our knowledge of male breast
cancer and potentially identify factors that might
affect outcome, and may also inform treatment
selection. 
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